Higher-Dose Semaglutide Injection Proves Mettle in Phase III Trials

(MedPage Today) — Tripling the weekly dose of semaglutide (Ozempic, Wegovy) resulted in greater weight loss compared with placebo in adults with obesity, both with and without type 2 diabetes, but did not increase the risk of serious adverse events…